China Medical System Holdings Ltd
SWB:2M7C
Gross Margin
China Medical System Holdings Ltd
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| HK |
C
|
China Medical System Holdings Ltd
SWB:2M7C
|
5.9B EUR |
73%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
663.9B USD |
83%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
56%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
424.9B USD |
68%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
203.6B CHF |
74%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
179.8B GBP |
82%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
192.2B CHF |
76%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.4T DKK |
84%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
211.9B USD |
78%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
183.4B USD |
68%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
142.9B USD |
74%
|
China Medical System Holdings Ltd
Glance View
China Medical System Holdings Ltd., a prominent player in the pharmaceutical industry, weaves its business model around the intricate pathway of driving market expansion through innovation and strategic partnerships. Founded with a vision to bring cutting-edge and specialized medicines to the Chinese healthcare market, CMS has established itself as a stalwart distributor and marketer. The company operates by obtaining licenses and distribution rights for pharmaceutical products primarily from European and North American manufacturers. By leveraging these international partnerships, CMS effectively bridges the gap between Western innovation and Chinese demand, tailoring its portfolio to include niche and differentiated therapeutic products that cater to the evolving needs of China's healthcare landscape. At the core of CMS's revenue model lies its proficiency in brand building and market penetration. Unlike the conventional pharmaceutical giants focusing solely on R&D, CMS maximizes its profits through strategic marketing and efficient distribution networks. By prioritizing products that require expert promotion to healthcare professionals, CMS utilizes its extensive sales force to ensure these products gain maximum visibility and acceptance in the marketplace. This business model not only fosters a symbiotic relationship with international pharmaceutical partners but also sustains a robust pipeline of new offerings. Therefore, with a strategic balancing act between global pharmaceutical expertise and local market intricacies, China Medical System Holdings Ltd. continues to fortify its position as a pivotal conduit in the dissemination of specialized medical solutions across China.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on China Medical System Holdings Ltd's most recent financial statements, the company has Gross Margin of 72.6%.
You don't have any saved screeners yet